Healthcare Resource Utilization 12 Months Following Initiation of Olanzapine/Samidorphan: Real-World Assessment of Patients With Bipolar I Disorder
Author(s)
Rakesh Jain, MD, MPH1, Hemangi R. Panchmatia, MSc2, Alejandro G. Hughes, MPH3, Michael J. Doane, PhD2, Hara E. Oyedeji, CRNP, MS4, Andrew J. Cutler, MD5;
1Department of Psychiatry, Texas Tech University School of Medicine-Permian Basin, Midland, TX, USA, 2Alkermes, Inc., Waltham, MA, USA, 3Optum, Inc., Eden Prairie, MN, USA, 4Fortitude Behavioral Health, Baltimore, MD, USA, 5Department of Psychiatry, SUNY Upstate Medical University, Syracuse, NY, USA
1Department of Psychiatry, Texas Tech University School of Medicine-Permian Basin, Midland, TX, USA, 2Alkermes, Inc., Waltham, MA, USA, 3Optum, Inc., Eden Prairie, MN, USA, 4Fortitude Behavioral Health, Baltimore, MD, USA, 5Department of Psychiatry, SUNY Upstate Medical University, Syracuse, NY, USA
Presentation Documents
OBJECTIVES: The combination of olanzapine and samidorphan (OLZ/SAM) provides the antipsychotic efficacy of olanzapine while mitigating olanzapine-associated weight gain. OLZ/SAM treatment was associated with significant reductions in acute healthcare resource utilization (HCRU) in a previous 6-month pre/post study. This study examined HCRU among patients with bipolar I disorder (BD-I) in the 12 months before and after OLZ/SAM initiation.
METHODS: Administrative claims data from October 18, 2020, to December 31, 2023, from the Komodo Healthcare Map were analyzed retrospectively. Adults with BD-I and continuous enrollment at least 12 months before (baseline) and after (follow-up) OLZ/SAM initiation were eligible. Inpatient (IP) admissions, emergency department (ED) and outpatient (OP) visits, and average numbers of IP days/patient were compared between baseline and follow-up. A secondary analysis was conducted in patients receiving OLZ/SAM for the full 12 months of follow-up.
RESULTS: Patients (n=1004; mean age: 39 years; female: 69%) were on average persistent for 173.7 days. Proportions of patients with 1 or more all-cause, mental health (MH)-related, and BD-I-related IP admissions and ED visits significantly decreased between baseline and follow-up (all P<0.001). Mean numbers of all-cause, MH-related, and BD-I-related IP days/patient decreased significantly (all P<0.001). Proportions of patients with OP visits were similar during baseline and follow-up. Larger reductions in IP admissions and ED visits were observed in patients receiving OLZ/SAM for the entire 12-month follow-up period (both P<0.001; n=300).
CONCLUSIONS: Among patients with BD-I, OLZ/SAM initiation results in clinically meaningful reductions in disease burden, as evidenced by reductions in hospital-based HCRU. Longer OLZ/SAM treatment retention was associated with improved effectiveness.
This study was sponsored by Alkermes, Inc. Medical writing and editorial support were provided by Peloton Advantage, LLC, an OPEN Health company, and funded by Alkermes, Inc.
METHODS: Administrative claims data from October 18, 2020, to December 31, 2023, from the Komodo Healthcare Map were analyzed retrospectively. Adults with BD-I and continuous enrollment at least 12 months before (baseline) and after (follow-up) OLZ/SAM initiation were eligible. Inpatient (IP) admissions, emergency department (ED) and outpatient (OP) visits, and average numbers of IP days/patient were compared between baseline and follow-up. A secondary analysis was conducted in patients receiving OLZ/SAM for the full 12 months of follow-up.
RESULTS: Patients (n=1004; mean age: 39 years; female: 69%) were on average persistent for 173.7 days. Proportions of patients with 1 or more all-cause, mental health (MH)-related, and BD-I-related IP admissions and ED visits significantly decreased between baseline and follow-up (all P<0.001). Mean numbers of all-cause, MH-related, and BD-I-related IP days/patient decreased significantly (all P<0.001). Proportions of patients with OP visits were similar during baseline and follow-up. Larger reductions in IP admissions and ED visits were observed in patients receiving OLZ/SAM for the entire 12-month follow-up period (both P<0.001; n=300).
CONCLUSIONS: Among patients with BD-I, OLZ/SAM initiation results in clinically meaningful reductions in disease burden, as evidenced by reductions in hospital-based HCRU. Longer OLZ/SAM treatment retention was associated with improved effectiveness.
This study was sponsored by Alkermes, Inc. Medical writing and editorial support were provided by Peloton Advantage, LLC, an OPEN Health company, and funded by Alkermes, Inc.
Conference/Value in Health Info
2025-05, ISPOR 2025, Montréal, Quebec, CA
Value in Health, Volume 28, Issue S1
Code
RWD82
Topic
Real World Data & Information Systems
Disease
No Additional Disease & Conditions/Specialized Treatment Areas, SDC: Mental Health (including addition)